Arrowhead Pharmaceuticals, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial toā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$55.05
Price+0.07%
$0.04
1Y
Price
Market Cap
$7.709b
Mid
Price/Earnings 3y Avg5y Avg
34.4x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+21.7%
EBITDA Margin+11.7%
Net Profit Margin+4.3%
Free Cash Flow Margin+21.7%
EBITDA Margin+11.7%
Net Profit Margin+4.3%
Free Cash Flow MarginRevenue
$1.091b
+31.5%
1y CAGR+7730.4%
3y CAGR+5797.5%
5y CAGREarnings
$202.265m
+12501.3%
1y CAGR+4136.3%
3y CAGR+3098.1%
5y CAGREPS
$1.54
+15500.0%
1y CAGR+5146.5%
3y CAGR+3856.1%
5y CAGRBook Value
$562.697m
$1.604b
Assets$1.041b
Liabilities$312.766m
DebtDebt to Assets
19.5%
0.8x
Debt to EBITDAFree Cash Flow
$322.007m
+105.3%
1y CAGR+49.5%
3y CAGR+18.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company